Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $120 price target.
June 14, 2024 | 2:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $120 price target.
The reiteration of an Overweight rating and a high price target of $120 by a reputable analyst from Cantor Fitzgerald is likely to positively impact ITCI's stock price in the short term. This indicates strong confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100